<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940804-2-00126</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Comments or objections should be received on or before September 6, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=4 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=4 -->  <USBUREAU>Drug Enforcement Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=4 -->  <DOCTITLE>Controlled Substances: Proposed Aggregate Production Quotas for 1995 </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Drug Enforcement Administration (DEA), Justice. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice of proposed aggregate production goals for 1995. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> This notice proposes initial 1995 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Comments or objections should be received on or before September 6, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Send comments or objections to the Administrator, Drug Enforcement Administration, Washington, DC 20537, Attn: DEA Federal Register Representative (CCR). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Howard McClain, Jr., Chief, Drug &amp; Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, Telephone: (202) 307&hyph;7183. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 1994). <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The quotas are to provide adequate supplies of each substance for: (1) The estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In determining the below listed proposed 1995 aggregate production quotas, the Deputy Administrator considered the following factors: (1) Total actual 1993 and estimated 1994 and 1995 net disposals of each substance by all manufacturers; (2) estimates of 1994 year end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; and (3) projected demand as indicated by procurement quota applications filed pursuant to &sect;1303.12 of Title 21 of the Code of Federal Regulations.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Pursuant to &sect;1303.23(c) of Title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1995, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1994 year-end inventory and actual 1994 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Therefore, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator pursuant to 59 FR 23637 (May 6, 1994), the Deputy Administrator hereby proposes that the aggregate production quotas for 1995 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L2,tp0,i1,s25,10 -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=95 g=1 f=1 --> &blank; <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Basic class  <!-- PJG 007 0150 intable --> 1Proposed 1995 quotas <!-- PJG 007 0152 intable -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0163 intable --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=2 --> Schedule I  <!-- PJG 007 0163 intable --> 0 <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 007 0162 intable --> s <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=01 g=1 f=2 --> Acetylmethadol  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Aminorex  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Bufotenine  <!-- PJG 007 0104 intable --> 10 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Cathinone  <!-- PJG 007 0104 intable --> 4 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Difenoxin  <!-- PJG 007 0104 intable --> 14,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2, 5-Dimethoxyamphetamine  <!-- PJG 007 0104 intable --> 15,650,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Dimethylamphetamine  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> N-Ethylamphetamine  <!-- PJG 007 0104 intable --> 4 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Lysergic acid diethylamide  <!-- PJG 007 0104 intable --> 41 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Mescaline  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4-Methoxyamphetamine  <!-- PJG 007 0104 intable --> 12 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4-Methylaminorex  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3-Methylfentanyl  <!-- PJG 007 0104 intable --> 12 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methaqualone  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methcathinone  <!-- PJG 007 0104 intable --> 9 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3, 4-Methyl <!-- PJG 0034 unknown --> ene <!-- PJG 0034 unknown --> di <!-- PJG 0034 unknown --> oxy <!-- PJG 0034 unknown --> am <!-- PJG 0034 unknown --> phet <!-- PJG 0034 unknown --> a <!-- PJG 0034 unknown --> mine  <!-- PJG 007 0104 intable --> 12 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3, 4-Methylene <!-- PJG 0034 unknown --> dioxy-N-ethyl <!-- PJG 0034 unknown --> am <!-- PJG 0034 unknown --> phetamine  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3, 4-Methylene <!-- PJG 0034 unknown --> dioxy <!-- PJG 0034 unknown --> meth <!-- PJG 0034 unknown --> amphetamine  <!-- PJG 007 0104 intable --> 12 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Normorphine  <!-- PJG 007 0104 intable --> 2 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Tetrahydrocannibinols  <!-- PJG 007 0104 intable --> 35,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Thiophene Analog of Phencyclidine  <!-- PJG 007 0104 intable --> 10 <!-- PJG /ITAG -->  <!-- PJG QTAG 03 --> <!-- PJG /QTAG -->  <!-- PJG 007 0162 intable --> s <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0163 intable --> 1 <!-- PJG ITAG l=21 g=1 f=2 --> Schedule II <!-- PJG 007 0163 intable --> 0 <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 007 0162 intable --> s <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=01 g=1 f=2 --> Alfentanil  <!-- PJG 007 0104 intable --> 7,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Amobarbital  <!-- PJG 007 0104 intable --> 5 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Amphetamine  <!-- PJG 007 0104 intable --> 635,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Cocaine  <!-- PJG 007 0104 intable --> 550,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Codeine (for sale)  <!-- PJG 007 0104 intable --> 67,312,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Codeine (for conversion)  <!-- PJG 007 0104 intable --> 16,181,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Desoxyephedrine 900,000 grams of levo <!-- PJG 0034 unknown --> des <!-- PJG 0034 unknown --> oxy <!-- PJG 0034 unknown --> ephedrine for use in a non <!-- PJG 0034 unknown --> con <!-- PJG 0034 unknown --> trolled, non <!-- PJG 0034 unknown --> prescrip <!-- PJG 0034 unknown --> tion product and 20 grams for methamphetamine  <!-- PJG 007 0104 intable --> 900,020 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Dextropropoxyphene  <!-- PJG 007 0104 intable --> 124,012,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Dihydrocodeine  <!-- PJG 007 0104 intable --> 202,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Diphenoxylate  <!-- PJG 007 0104 intable --> 688,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Ecgonine (for conversion)  <!-- PJG 007 0104 intable --> 650,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Fentanyl  <!-- PJG 007 0104 intable --> 76,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Hydrocodone  <!-- PJG 007 0104 intable --> 8,474,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Hydromorphone  <!-- PJG 007 0104 intable --> 393,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Levo-alpha-acetylmethadol  <!-- PJG 007 0104 intable --> 200,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Levorphanol  <!-- PJG 007 0104 intable --> 8,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Meperidine  <!-- PJG 007 0104 intable --> 8,637,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methadone  <!-- PJG 007 0104 intable --> 3,779,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methadone (for conversion)  <!-- PJG 007 0104 intable --> 364,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methadone Intermediate (for sale)  <!-- PJG 007 0104 intable --> 300,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methadone Intermediate (for conversion)  <!-- PJG 007 0104 intable --> 4,393,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Methylphenidate  <!-- PJG 007 0104 intable --> 7,935,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Morphine (for sale)  <!-- PJG 007 0104 intable --> 7,612,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Morphine (for conversion)  <!-- PJG 007 0104 intable --> 78,105,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Noroxymorphone (for sale)  <!-- PJG 007 0104 intable --> 21,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Noroxymorphone (for conversion)  <!-- PJG 007 0104 intable --> 3,500,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Opium  <!-- PJG 007 0104 intable --> 1,118,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Oxycodone (for sale)  <!-- PJG 007 0104 intable --> 3,613,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Oxycodone (for conversion)  <!-- PJG 007 0104 intable --> 6,200 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Oxymorphone  <!-- PJG 007 0104 intable --> 2,500 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Pentobarbital  <!-- PJG 007 0104 intable --> 15,706,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Phencyclidine  <!-- PJG 007 0104 intable --> 52 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Phenylacetone (for conversion)  <!-- PJG 007 0104 intable --> 3,528,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Secobarbital  <!-- PJG 007 0104 intable --> 480,000 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Sufentanil  <!-- PJG 007 0104 intable --> 700 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Thebaine  <!-- PJG 007 0104 intable --> 9,383,000 <!-- PJG /ITAG -->  </TABLE>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=2 --> Aggregate production quotas for all other Schedules I and II controlled substances included in &sect;&sect;1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations are established at zero.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , summarizing the issues to be heard and setting the time for the hearing.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C., 601,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> et seq <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 28, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Stephen H. Greene,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Administrator. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;19054 Filed 8&hyph;3&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4410&hyph;09&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            